Decreased GABAA and GABAB receptor functional activity in cannabinoid CB1 receptor knockout mice.
The interaction between brain GABAergic and endocannabinoid systems was evaluated by examining the quantitative and functional status of GABAergic receptors in cannabinoid CB(1) receptor knockout (CB(1)(-/-)) mice. To this aim, GABA(A) ([(3)H]-Muscimol binding assay), GABA(B) (baclofen-stimulated [(35)S]-GTPγS binding assay), GABA(A)α(1), GABA(A)α(2) and GABA(A)γ(2) receptors gene expression (real-time reverse transcriptase polymerase chain reaction [PCR]) were carried out in CB(1)(-/-) and wild-type mice (CB(1)(+/+)). [(3)H]-Muscimol binding assays revealed significant reduction in the density of GABA(A) receptors in CA2 (30%) and DG (28%) of the hippocampus, thalamus (40%), cingulate (28%) and motor cortex (35%) of CB(1)(-/-) mice. Functional activity of metabotropic GABA(B) receptors was measured by evaluating the ability of GABA(B) agonist baclofen to stimulate [(35)S]-GTPγS binding. The results showed significant reduced [(35)S]-GTPγS binding in CA1 (61%), CA3 (51%) and DG (60%) of CB(1)(-/-) mice compared with CB(1)(+/+) mice. Real-time reverse transcriptase PCR was carried out for evaluating gene expression of α(1), α(2) and γ(2) subunits of GABA(A) receptor in the amygdala. The results showed significant reduced GABA(A)α(1) (50%) and GABA(A)α(2) (40%) receptor subunits gene expression in the amygdala of CB(1)(-/-) mice. No difference was observed in GABA(A)γ(2) receptor subunit gene expression. This study provides strong evidence of the involvement of CB(1) receptors in the control of GABAergic responses mediated by GABA(A) and GABA(B) receptors, and suggests a possible role of the endocannabinoid system in the regulation of anxiety-related disorders.
Departamento de Farmacología, Facultad de Medicina, Universidad del País Vasco, UPV/EHU, Leioa, Bizkaia, Spain.
Leyre
L
Urigüen
María S
MS
García-Gutiérrez
Jorge
J
Manzanares
D000818:Animals; D001418:Baclofen / Q000378:metabolism; D001921:Brain / Q000378:metabolism / Q000502:physiology; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D058785:GABA-A Receptor Agonists / Q000378:metabolism; D058786:GABA-B Receptor Agonists / Q000378:metabolism; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009118:Muscimol / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics* / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000235:genetics / Q000378:metabolism*
D063385:Cannabinoid Receptor Modulators; D058785:GABA-A Receptor Agonists; D058786:GABA-B Receptor Agonists; D043884:Receptor, Cannabinoid, CB1; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D009118:Muscimol; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D001418:Baclofen